



PRESS RELEASE

FOR IMMEDIATE RELEASE

DECHRA VETERINARY PRODUCTS COMPLETES NORTH AMERICAN EXPANSION WITH MEXICAN ACQUISITION

Dechra Acquires Laboratorios Brovel, S.A. de C.V.

OVERLAND PARK, KS, January 13, 2016 – Dechra Veterinary Products, a leading manufacturer, distributor and marketer of veterinary pharmaceuticals announces expansion of its North American business into the Mexican Veterinary Animal Health Market. Dechra acquired 100% of the share capital of Laboratorios Brovel, S.A. de C.V. (Brovel), a veterinary pharmaceuticals company based in Mexico City.

Brovel is a family-owned business with more than 52 years' experience in the production and distribution of pharmaceutical veterinary products. It has a diverse product portfolio and will help open the Mexican animal health market to Dechra as well as the potential to access other Latin



The Bravo Family and Mike Eldred

American markets in the future. Mexico is one of the top fifteen markets for animal health globally and within that market, Brovel is one of the top twenty companies and has produced double digit growth for many years.

The initial focus following the acquisition will be to achieve registration of several existing Dechra products in Mexico.

“Following our success with expansion into the Canadian animal health market, the acquisition of Brovel will solidify our presence as a dominant animal health company in North America”, said Mike Eldred, President of North American Operations. “The team at Brovel will be instrumental to expanding the Dechra portfolio of veterinary products into Mexico and serving the veterinary community there.”

For the six month period ending December 31, 2015, Dechra's total reported North American revenue increased by approximately 51% at CER on the same period last year (57% at AER) as our dermatology, endocrinology and ophthalmic ranges started the year strongly. The momentum in the US and Canada is continuing to build due to a strong investment in sales, marketing and technical support. With less than a full year of trading, Canada contributed meaningfully to the period-on-period growth.

About Dechra

Dechra Veterinary Products, located in Overland Park, Kansas is the U.S. sales and marketing division of Dechra Pharmaceuticals PLC, a UK listed company dedicated to the animal healthcare market. Dechra Veterinary Products' companion animal portfolio includes VETORYL[®] Capsules (trilostane), FELIMAZOLE[®] (methimazole) Coated Tablets, ANIMAX[®] OINTMENT (nystatin, neomycin sulfate, thiostrepton, triamcinolone acetonide ointment), VETROPOLYCIN[®] (bacitracin-neomycin-polymyxin) Veterinary Ophthalmic Ointment and VETROPOLYCIN[®] HC (bacitracin-neomycin-polymyxin-hydrocortisone acetate 1%) Veterinary Ophthalmic Ointment, PHYCOX[®] joint health supplements, MURICIN[®] (mupirocin ointment 2%), as well as an extensive topical dermatologic line for veterinary use. Dechra's equine portfolio includes OSPHOS[®] (clodronate injection), Orthokine[®] vet irap 10 and 60, Osteokine[®] (PRP), and EQUIDONE[®] (domperidone) Gel.

For more information, please visit www.dechra-us.com or call (866) 933-2472.

Contact:

Mike Eldred
President, North American Operations
Dechra Veterinary Products
mike.eldred@dechra.com

Doug Hubert
Vice President, Sales and Marketing
Dechra Veterinary Products
doug.hubert@dechra.com